JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, M. R.
Right arrow Articles by Axelson, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, M. R.
Right arrow Articles by Axelson, J. E.

Clearance and disposition of ritodrine in the fluid compartments of the fetal lamb during and after constant rate fetal intravenous infusion

MR Wright, DW Rurak, MP van der Weyde, SM Taylor and JE Axelson

Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.

The disposition of the beta-2 adrenoreceptor agonist, ritodrine, has been examined in the fetal lamb during and after constant rate fetal intravenous infusion (8-24 h). Samples were collected from the fetal femoral artery, umbilical vein, maternal femoral artery, uterine vein, fetal trachea and the amniotic activity for ritodrine quantitation. The amniotic fluid was also analyzed for conjugated metabolites of ritodrine. Ritodrine appears to be cleared across the sheep placenta only to a limited extent (placental clearance 9.2 +/- 2 ml/min/kg; mean +/- S.E.M.). There is, however, significant fetal nonplacental clearance of ritodrine (fetal nonplacental clearance 52.8 +/- 8.0 ml/min/kg). At least part of this clearance appears to be due to fetal drug metabolism, as evidenced by the accumulation of glucuronide conjugates of ritodrine in the amniotic fluid. Ritodrine was also shown to accumulate in the amniotic and fetal tracheal fluids and persist after fetal arterial plasma ritodrine concentrations became undetectable. The accumulation of ritodrine in the tracheal fluid may be of pharmacologic significance, given the well documented, potent effects of beta-2 agonists on fetal lung function and development.

Volume 258, Issue 3, pp. 897-902, 09/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
J. Kim, K. W. Riggs, and D. W. Rurak
STEREOSELECTIVE PHARMACOKINETICS OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS IN PREGNANT SHEEP
Drug Metab. Dispos., February 1, 2004; 32(2): 212 - 221.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Kumar, H. Wong, S. A. Yeung, K. W. Riggs, F. S. Abbott, and D. W. Rurak
Disposition of Valproic Acid in Maternal, Fetal, and Newborn Sheep I: Placental Transfer, Plasma Protein Binding, and Clearance
Drug Metab. Dispos., July 1, 2000; 28(7): 845 - 856.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
S. Kumar, H. Wong, S. A. Yeung, K. W. Riggs, F. S. Abbott, and D. W. Rurak
Disposition of Valproic Acid in Maternal, Fetal, and Newborn Sheep II: Metabolism and Renal Elimination
Drug Metab. Dispos., July 1, 2000; 28(7): 857 - 864.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
S. Kumar, K. W. Riggs, and D. W. Rurak
Comparative Formation, Distribution, and Elimination Kinetics of Diphenylmethoxyacetic Acid (a Diphenhydramine Metabolite) in Maternal and Fetal Sheep
Drug Metab. Dispos., April 1, 1999; 27(4): 463 - 470.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1991 by the American Society for Pharmacology and Experimental Therapeutics.